



Dear Healthcare Professional,

As part of our ongoing efforts to further understand the findings related to the cases of progressive multifocal leukoencephalopathy (PML) in the TYSABRI® (natalizumab) clinical trials we convened a panel of scientific experts on March 4<sup>th</sup>, 2005. The panel reviewed the two cases of confirmed PML, as well as the biology of the JC virus, the etiological agent of PML. Criteria for the diagnosis of PML were discussed.

The panel's consensus was that CSF analysis for JC virus was the most sensitive and specific test to confirm the diagnosis of PML in patients with clinical and MRI findings suggestive of PML. The panel also noted that restoration of the normal immune state might contribute towards clinical stabilization and survival.

During the panel meeting, participants discussed Biogen Idec's reviews of safety databases completed to date, which revealed no previously reported cases of PML in multiple sclerosis patients treated with interferon beta monotherapy. According to information on FDA's website, FDA has analyzed data in its post-marketing database and not found any cases of PML reported in patients receiving a beta- interferon.

It remains unclear why PML developed in the two patients treated with combination therapy of TYSABRI and AVONEX® (Interferon beta-1a).

We are extensively evaluating TYSABRI-treated patients in clinical trials. Because we believe in the promising therapeutic benefit of TYSABRI, we are working to complete these evaluations expeditiously. In addition, we remain in close contact with the FDA and other Regulatory Authorities, as well as the advisory and safety monitoring committees for the TYSABRI trials.

Thank you for your patience and continued support over the past few weeks. We will continue to inform you of important new developments or changes. In the meantime, please contact Medical Information at 1-888-489-7227 with any questions.

Sincerely,

A handwritten signature in black ink, appearing to read "Whaijen Soo".

Whaijen Soo, MD PhD  
Senior Vice President  
Medical Research  
Biogen Idec

A handwritten signature in black ink, appearing to read "Lars Ekman".

Lars Ekman, MD, PhD  
Executive Vice President and President  
Global Research and Development  
Elan Pharmaceuticals